Abbott's Bardoxolone in Phase III - Zacks.com PDF Print
Zacks.com
The multinational, double-blind, placebo-controlled phase III study, BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), will be conducted with about 1600 patients across

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.